Sinergitas Efek Kombinasi Ekstrak Daun SirsaK (Annona muricata Linn) Dengan Doksorubisin Pada Sel Kanker Payudara MCF-7

Lukman; Hijral Aswad; Desy Ayu Lestari; Andi Paluseri

doi:10.32382/mf.v20i2.832

Penulis

Lukman Universitas Almarisah Madani, Makassar, Indonesia https://orcid.org/0000-0002-5703-3714
Hijral Aswad Universitas Megarezky, Makassar, Indonesia https://orcid.org/0009-0004-4432-1153
Desy Ayu Lestari Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin, Banjarmasin, Indonesia https://orcid.org/0009-0007-9955-9769
Andi Paluseri Universitas Almarisah Madani, Makassar, Indonesia https://orcid.org/0009-0000-3023-5714

DOI:

https://doi.org/10.32382/mf.v20i2.832

Kata Kunci:

Annoa muricata, Anti kanker, MCF-7, Sinergitas

Abstrak

Synergistic Effect Of Combination Of Soursop Leaf Extract (Annona Muricata Linn) With Doxorubicin On Mcf-7 Breast Cancer Cells

Doxorubicin is the first line of cancer treatment but has very serious side effects such as hair loss, kidney damage and liver function abnormalities. One strategy to reduce these side effects is to combine doxorubicin with medicinal plants with anti-cancer properties such as soursop leaves (Anona muricata Linn). The aim of this research is to determine the synergistic effect of the combination of soursop leaf extract with doxorubicin to inhibit the growth of MCF-7 breast cancer cells. Soursop leaves were extracted with 96% ethanol while the anti-cancer test used the MTT method. The results of the study showed that soursop leaf extract had anti-cancer properties with IC₂₅ and IC₅₀ respectively being 29.36 ± 1.16 and 58.75 ± 2.35 µg/mL while doxorubicin was 1.34 ± 0.04 and 2. 76 ± 0.03 µg/mL. The combination of soursop leaf extract and doxorubicin showed a value of 0.8-1.0 (moderate synergistic). So it can be concluded that the combination of soursop leaf extract and doxorubicin shows a synergistic effect.

Doksorubisin merupakan lini pertama pengobatan penyakit kanker akan tetapi memiliki efek samping sangat serius seperti kerontokan rambut, kerusakan ginjal dan kelainan fungsi hati. Salah satu strategi untuk mengurangi efek samping tersebut dengan mengombinasikan doksorubisin dengan tanaman obat berkhasiat anti kanker seperti daun sirsak (Anona muricata Linn). Tujuan penelitian ini adalah mengetahui efek sinergitas kombinasi ekstrak daun A. muricata dengan doksorubisin untuk menghambat pertumbuhan sel kanker payudara MCF-7. Daun A. muricata diekstraksi secara maserasi menggunakan etanol 96%. Aktivitas anti kanker diuji menggunakan metode MTT. Uji sinergitas dilakukan dengan mengombinasikan antara IC₂₅ dan IC₅₀ dari ekstrak daun A. muricata dengan doksorubisin. Hasil penelitian menunjukkan bahwa ekstrak etanol daun A. muricata berkhasiat sebagai anti kanker dengan nilai IC₂₅ dan IC₅₀ secara berturut-turut adalah 29,36 ± 1,16 dan 58,75 ± 2,35 µg/mL dibandingkan dengan doksorubisin sebesar 1,34 ± 0,04 dan 2,76 ± 0,03 µg/mL. Kombinasi antara ekstrak etanol daun A. muricata dengan doksorubisin menunjukkan nilai 0,8 - 1,0 (sinergis sedang). Sehingga dapat disimpulkan bahwa kombinasi antara ekstrak etanol daun A. muricata dengan doksorubisin menunjukkan efek yang sinergis

Referensi

Bhanuwati AV, Pakpahan A. 2022. Cytotoxic test of different solvents of soursop (Annona muricata) leaf extract against HSC-3 cell line. Dental J, 55(3); 130-36.

Bijnsdorp IV, Giovannetti E, Peters GJ. 2011. Analysis of drug interactions, in: Cree, IA, Cancer cell culture: Methods and protocols. Humana Press. Totowa, New Jersey.

Calzetta L, Koziol-White C. 2021. Pharmacological interactions: Synergism, or not synergism, that is the question. Curr Res Pharmacol Drug Discov, 2; e100046.

Dewidar SA, Hamdy O, Soliman MM, El Gayar AM, El-Mesery M. 2023. Enhanced therapeutic efficacy of doxorubicin/cyclophosphamide in combination with pitavastatin or simvastatin against breast cancer cells. Med Oncol, 41(1); e7.

Duarte D, Vale N. 2022. Evaluation of synergism in drug combinations and reference models for future orientations in oncology. Curr Res Pharmacol Drug Discov, 3; e100110.

Fatmawati D, Suparmi, Yusuf I, Israhnanto. 2018. Selektivitas antikanker ekstrak daun sirsak (Annona muricata) pada lini sel kanker payudara. Bio-site, 4(2); 78-83.

Ghanem A, Ali MA, Elkady MA, Abdel Mageed SS, El Hassab MA, El-Ashrey MK, Mohammed OA, Doghish AS. 2023. Rumex vesicarius L. boosts the effectiveness of sorafenib in triple-negative breast cancer by downregulating BCl2, mTOR, and JNK, and upregulating p21 expression. Pathol Res Pract, 250(Oct); e154807.

González-Larraza PG, López-Goerne TM, Padilla-Godínez FJ, González-López MA, Hamdan-Partida A, Gómez E. 2020. IC50 evaluation of platinum nanocatalysts for cancer treatment in fibroblast, HeLa, and DU-145 cell lines. ACS Omega, 5(39); 25381-89.

Hanifah ZN, Da’i M. 2022. Uji aktivitas sitotoksik kombinasi doksorubisin dan ekstrak etanol daun kemangi (Ocimum sanctum L.) terhadap sel MCF-7. Usadha Journal of Pharmacy, 1(3); 322-31.

Hasan AEZ, Julistiono H, Bermawie N, Riyanti EI, Arifni FR. 2022. Soursop leaves (Annona muricata L.) endophytic fungi anticancer activity against HeLa cells. Saudi J Biol Sci, 29(8); e103354.

Hasyim RMS, Yuniarti L, Andriane Y. 2023. Efek antikanker dan ko-kemoterapi nanopartikel alginat ekstrak etanol daun sirsak (Annona muricata) dengan doxorubicin pada kultur sel kanker serviks uteri (HeLa). Bandung conference series: Medical science, 3(1); 113-22.

Ibrahim A, Sandhika W, Budipramana VS. 2020. Uji efektifitas ekstrak etanol daun Annona muricata terhadap sel kanker payudara MCF-7. Journal of Health Management, 6(1); 64-72.

Jacobo-Herrera N, Pérez-Plasencia C, Castro-Torres VA, Martínez-Vázquez M, González-Esquinca AR, Zentella-Dehesa A. 2019. Selective acetogenins and their potential as anticancer agents. Front Pharmacol, 10; e783.

Liu J, Minemoto Y, Lin A. 2004. c-Jun N-terminal protein kinase 1 (JNK1), but not JNK2, is essential for tumor necrosis factor alpha-induced c-Jun kinase activation and apoptosis. Mol Cell Biol, 24(24); 10844-56.

Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. 2021. Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers (Basel), 13(17); e4287.

Lukman L, Marwati M, Mus S, Syahruni R. 2021. Uji sitotoksik ekstrak daun murbei (Morul alba L) terhadap sel kanker MCF-7 dan selektifitasnya. Medical J, 4(2); 62-66.

Marinello J, Delcuratolo M, Capranico G. 2018. Anthracyclines as topoisomerase II poisons: From early studies to new perspectives. Int J Mol Sci, 19(11); e3480.

Mutakin M, Fauziati R, Fadhilah FN, Zuhrotun A, Amalia R, Hadisaputri YE. 2022. Pharmacological activities of soursop (Annona muricata Lin.). Molecules, 27(4); e1201.

Nordin N, Khimani K, Abd Ghani MF. 2021. Acetogenins exhibit potential BCL-XL inhibitor for the induction of apoptosis in the molecular docking study. Curr Drug Discov Technol, 18(6); e010921191171.

Plasay M, Muslimin L. 2024. Melittin, a potential natural toxin with anticancer properties: Regulating IL-1β, COX-2 and TNF-α in human colorectal cancer cells WiDr. Trends Sci, 21(4); e7424.

Siegel RL, Miller KD, Wagle NS, Jemal A. 2023. Cancer statistics, 2023. CA Cancer J Clin, 73(1); 17-48.

Sritharan S, Sivalingam N. 2021. A comprehensive review on time-tested anticancer drug doxorubicin. Life Sci, 278(Aug); e119527.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 71(3); 209-49.

Taymaz-Nikerel H, Karabekmez ME, Eraslan S, Kırdar B. 2018. Doxorubicin induces an extensive transcriptional and metabolic rewiring in yeast cells. Sci Rep, 8(1); e13672.

Upadhyay A. 2021. Cancer: An unknown territory; rethinking before going ahead. Genes Dis, 8(5); 655-61.

Xu S, Murtagh S, Han Y, Wan F, Toriola AT. 2024. Breast cancer incidence among US women aged 20 to 49 years by race, stage, and hormone receptor status. JAMA Netw Open, 7(1); e2353331-e31.

Yamamoto K, Kawamoto S, Chijiki R, Watanabe M, Matsumoto S, Kitao A, Mizutani Y, Kajimoto K, Hayashi Y, Yakushijin K, Minami H. 2023. Biclonal diffuse large B-cell lymphoma commonly characterized by partial trisomy 18q involving MALT1 and Bcl2. Intern Med, 62(2); 285-92.

Zou Z, Tao T, Li H, Zhu X. 2020. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci, 10(1); e31.